TNGX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tango Therapeutics (TNGX) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock has strong positive catalysts, bullish technical indicators, and favorable analyst sentiment, making it a compelling long-term growth opportunity despite short-term financial challenges.
The stock is currently in a bullish trend with MACD histogram at 0.393 (positively expanding), RSI at 87.315 (overbought), and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). The current price of $17 is above the key pivot level of $13.81, with resistance levels at $16.414 and $18.023.
Collaboration with Erasca to test a new cancer therapy, driving a 24% stock price increase to a 52-week high.
Boxer Capital Management significantly increased its stake in Tango, now owning 21.09% of the company.
Analysts have raised price targets (e.g., H.C. Wainwright to $27, Guggenheim to $
and maintain Buy ratings, citing strong potential for vopimetostat in oncology.
Positive sentiment from news and clinical trial developments.
Financial performance shows no revenue in Q4 2025, with a YoY decline of -100%.
EPS dropped to -0.29, down -14.71% YoY, and net income remains negative at -$38.75M.
RSI indicates the stock is overbought, suggesting potential for short-term pullback.
In Q4 2025, the company reported zero revenue (-100% YoY), a net income of -$38.75M (up 2.86% YoY), and an EPS of -0.29 (down -14.71% YoY). Gross margin dropped to 0, reflecting the company's early-stage biotech status and reliance on future clinical trial success.
Analysts are bullish on TNGX, with multiple firms raising price targets (e.g., H.C. Wainwright to $27, Guggenheim to $20) and maintaining Buy ratings. Analysts highlight the potential of vopimetostat as a first-in-class oncology therapy and expect significant outperformance driven by upcoming clinical trial results in 2026.
